Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Vaginal brachytherapy more toxic than pelvic RT in endometrial carcinoma

Publish date:: April 30, 2019

Key clinical point: Vaginal cuff brachytherapy plus chemotherapy showed higher acute toxicity compared with pelvic radiation therapy in patients with early-stage endometrial carcinoma.

Major finding: Vaginal brachytherapy plus chemotherapy was not superior over pelvic RT in terms of 60-month recurrence-free survival (HR, 0.92; 90% confidence limit, 0.69-1.23).

Study details: A phase 3 trial of 601 patients with early-stage endometrial cancer.

Disclosures: The study was supported by grant funding from the National Cancer Institute and the Memorial Sloan Kettering Cancer Center. The authors reported financial affiliations with AstraZeneca, Genentech, Genmab, Janssen, Johnson & Johnson, Tesaro, and several others.

Citation:

Randall ME et al. J Clin Oncol. 2019 Apr 17. doi: 10.1200/JCO.18.01575.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Gynecologic Cancer

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

Is diagnostic hysteroscopy safe in patients with type 2 endometrial cancer?,

Cervical cancer recurrence patterns differ after laparoscopic and open hysterectomy,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,